CA2477163C - Soluble form of carbonic anhydrase ix (s-ca-ix), assays to detect s-ca ix, and ca ix's coexpression with her-2/neu/c-erbb-2, and ca ix-specific monoclonal antibodies to non-immunodominant epitopes - Google Patents

Soluble form of carbonic anhydrase ix (s-ca-ix), assays to detect s-ca ix, and ca ix's coexpression with her-2/neu/c-erbb-2, and ca ix-specific monoclonal antibodies to non-immunodominant epitopes Download PDF

Info

Publication number
CA2477163C
CA2477163C CA2477163A CA2477163A CA2477163C CA 2477163 C CA2477163 C CA 2477163C CA 2477163 A CA2477163 A CA 2477163A CA 2477163 A CA2477163 A CA 2477163A CA 2477163 C CA2477163 C CA 2477163C
Authority
CA
Canada
Prior art keywords
antibodies
protein
domain
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2477163A
Other languages
English (en)
French (fr)
Other versions
CA2477163A1 (en
Inventor
Jaromir Pastorek
Silvia Pastorekova
Miriam Zatovicova
Jan Zavada
Marta Ortova Gut
Zuzanna Zavadova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomedical Research Centre Of Slovak Academy Of Sciences
Original Assignee
Institute of Virology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Virology filed Critical Institute of Virology
Priority to CA2704273A priority Critical patent/CA2704273C/en
Priority claimed from PCT/US2003/005136 external-priority patent/WO2003100029A2/en
Publication of CA2477163A1 publication Critical patent/CA2477163A1/en
Application granted granted Critical
Publication of CA2477163C publication Critical patent/CA2477163C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2477163A 2002-02-21 2003-02-21 Soluble form of carbonic anhydrase ix (s-ca-ix), assays to detect s-ca ix, and ca ix's coexpression with her-2/neu/c-erbb-2, and ca ix-specific monoclonal antibodies to non-immunodominant epitopes Expired - Fee Related CA2477163C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2704273A CA2704273C (en) 2002-02-21 2003-02-21 Mn/ca ix-antibody binding specifically to non-immunodominant epitope of mn/ca ix and uses thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35882402P 2002-02-21 2002-02-21
US60/358,824 2002-02-21
US38306802P 2002-05-23 2002-05-23
US60/383,068 2002-05-23
US43149902P 2002-12-05 2002-12-05
US60/431,499 2002-12-05
PCT/US2003/005136 WO2003100029A2 (en) 2002-02-21 2003-02-21 Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2704273A Division CA2704273C (en) 2002-02-21 2003-02-21 Mn/ca ix-antibody binding specifically to non-immunodominant epitope of mn/ca ix and uses thereof

Publications (2)

Publication Number Publication Date
CA2477163A1 CA2477163A1 (en) 2003-12-04
CA2477163C true CA2477163C (en) 2010-07-27

Family

ID=33425052

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2477163A Expired - Fee Related CA2477163C (en) 2002-02-21 2003-02-21 Soluble form of carbonic anhydrase ix (s-ca-ix), assays to detect s-ca ix, and ca ix's coexpression with her-2/neu/c-erbb-2, and ca ix-specific monoclonal antibodies to non-immunodominant epitopes

Country Status (9)

Country Link
US (5) US7846673B2 (enExample)
EP (1) EP1487972B1 (enExample)
JP (4) JP4488351B2 (enExample)
AU (1) AU2003217606C1 (enExample)
CA (1) CA2477163C (enExample)
DK (2) DK3031910T3 (enExample)
HK (1) HK1226095B (enExample)
HU (3) HUE036891T2 (enExample)
WO (1) WO2004005348A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2508596T3 (en) * 2002-02-21 2015-10-19 Inst Virology MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use.
AU2003217606C1 (en) * 2002-02-21 2008-07-17 Institute Of Virology Soluble Form of Carbonic Anhydrase IX (s-CA IX), Assays to Detect s-CA IX, CA IXs Coexpression with HER-2/neu/c-erbB-2 and CA IX-Specific Monoclonal Antibodies to Non-Immunodominant Epitopes
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
ATE437235T1 (de) * 2002-04-16 2009-08-15 Univ California Verfahren zur prognose von nierenzellkarzinom und behandlungsauswahl mit carboanhydrase ix
US20090239247A1 (en) * 2002-12-13 2009-09-24 Harris Adrian L MN and Hypoxia
ZA200800314B (en) 2005-06-29 2009-09-30 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
AU2007324128B2 (en) * 2006-10-10 2013-10-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
US7820159B2 (en) * 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
WO2009056342A1 (en) * 2007-11-02 2009-05-07 Wilex Ag Binding epitopes for g250 antibody
ES2685596T3 (es) 2007-11-19 2018-10-10 Asahi Kasei Kabushiki Kaisha Derivados éster de ácido carbámico para la producción de isocianato y compuestos hidroxi aromáticos
EP4032538A3 (en) 2009-03-02 2022-10-26 Massachusetts Institute of Technology Methods and products for in vivo enzyme profiling
EP2295975B1 (en) * 2009-09-10 2014-06-18 Bruker Daltonik GmbH Determining the expression status of human epidermal growth factor receptor 2 (HER2) in biological samples
ES2881535T3 (es) 2011-03-15 2021-11-29 Massachusetts Inst Technology Detección multiplexada con indicadores codificados con isótopos
US9080849B2 (en) 2011-07-29 2015-07-14 Milwaukee Electric Tool Corporation Tape measure
CA2784047C (en) 2011-07-29 2015-08-11 Milwaukee Electric Tool Corporation Tape measure
US8863399B2 (en) 2011-08-26 2014-10-21 Milwaukee Electric Tool Corporation Tape measure
EP2508890A1 (en) * 2011-10-25 2012-10-10 Roche Diagnostics GmbH CAIX based diagnosis of heart failure
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
US9267778B2 (en) 2012-01-19 2016-02-23 Milwaukee Electric Tool Corporation Tape measure
WO2013116385A1 (en) * 2012-01-31 2013-08-08 Threshold Pharmaceuticals, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
JP2015155795A (ja) * 2012-05-21 2015-08-27 東レ株式会社 癌の検出方法
USD733597S1 (en) 2012-07-30 2015-07-07 Milwaukee Electric Tool Corporation Tape measure
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
JP6847660B2 (ja) * 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
EP3286337A4 (en) * 2015-04-23 2018-12-12 Cedars-Sinai Medical Center Automated delineation of nuclei for three dimensional (3-d) high content screening
USD785476S1 (en) 2015-12-10 2017-05-02 Milwaukee Electric Tool Corporation Tape measure
USD785475S1 (en) 2015-12-10 2017-05-02 Milwaukee Electric Tool Corporation Tape measure
USD787347S1 (en) 2016-01-07 2017-05-23 Milwaukee Electric Tool Corporation Tape measure
USD783429S1 (en) 2016-01-07 2017-04-11 Milwaukee Electric Tool Corporation Tape measure
USD783430S1 (en) 2016-01-07 2017-04-11 Milwaukee Electric Tool Corporation Tape measure
EP3440013A4 (en) 2016-04-08 2021-03-17 Massachusetts Institute of Technology METHOD FOR SPECIFIC PROFILING OF PROTEASE ACTIVITY ON LYMPH NODES
WO2017193070A1 (en) 2016-05-05 2017-11-09 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
USD788611S1 (en) 2016-06-01 2017-06-06 Milwaukee Electric Tool Corporation Tape measure
CA3037767A1 (en) 2016-09-28 2018-04-05 Georgia Tech Research Corporation Methods and compositions for noninvasive detection of organ transplant rejection
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
EP3559018A1 (en) 2016-12-23 2019-10-30 Bicyclerd Limited Peptide derivatives having novel linkage structures
AU2018248327B2 (en) 2017-04-07 2024-10-10 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
WO2019173332A1 (en) 2018-03-05 2019-09-12 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US11028425B2 (en) 2018-06-08 2021-06-08 Glympse Bio, Inc. Diagnosis and monitoring of liver disease
US11732009B2 (en) 2018-06-08 2023-08-22 Glympse Bio, Inc. Activity sensor with tunable analyte
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
EP3856921B1 (en) 2018-09-25 2026-04-29 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
EP3911753A1 (en) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Sensors for detecting and imaging of cancer metastasis
CA3131900A1 (en) 2019-02-28 2020-09-24 Georgia Tech Research Corporation Compositions and methods for logic-gated profiling of biologic activity
WO2020226612A1 (en) * 2019-05-06 2020-11-12 Navi Bio-Therapeutics, Llc Anti-carbonic anhydrase ix antibody
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
IL292413A (en) * 2019-11-05 2022-06-01 Mabpro A S Humanized anti-ca ix antibodies and methods of using them
CN111273036B (zh) * 2020-03-06 2021-06-15 中国农业科学院兰州兽医研究所 检测口蹄疫非结构蛋白抗体的单抗竞争化学发光试剂盒
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头
EP4211468A4 (en) 2020-09-11 2024-10-09 Glympse Bio, Inc. DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
CN116167592B (zh) * 2023-04-20 2023-06-23 交通运输部天津水运工程科学研究所 一种河流溢油风险防控和决策支持系统

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US6069242A (en) 1992-03-11 2000-05-30 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6027887A (en) 1992-03-11 2000-02-22 Institute Of Virology, Solvak Academy Of Sciences MN gene and protein
US5972353A (en) 1992-03-11 1999-10-26 Institute Of Virology, Slovak Academy Of Sciences MN proteins, polypeptides, fusion proteins and fusion polypeptides
US6297051B1 (en) 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5981711A (en) 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
US6093548A (en) 1992-03-11 2000-07-25 Institute Of Virology, Slovak Academy Of Sciences Detection and quantitation of MN-specific antibodies.
US5989838A (en) 1992-03-11 1999-11-23 Institute Of Virology, Slovak Academy Of Sciences Immunological methods of detecting MN proteins and MN polypeptides
US5387676A (en) 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6774117B1 (en) 1992-03-11 2004-08-10 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6297041B1 (en) * 1992-03-11 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6204370B1 (en) 1992-03-11 2001-03-20 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5955075A (en) 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
WO1995034650A2 (en) * 1994-06-15 1995-12-21 Ciba Corning Diagnostics Corp. Mn gene and protein
US6451977B1 (en) * 1998-02-26 2002-09-17 Genentech, Inc. Fused polypeptides
AU758957C (en) 1998-10-23 2004-08-12 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
AU2002351208A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
AU2003217606C1 (en) * 2002-02-21 2008-07-17 Institute Of Virology Soluble Form of Carbonic Anhydrase IX (s-CA IX), Assays to Detect s-CA IX, CA IXs Coexpression with HER-2/neu/c-erbB-2 and CA IX-Specific Monoclonal Antibodies to Non-Immunodominant Epitopes
EP1576010A4 (en) 2002-08-23 2006-12-27 Chiron Corp THERAPEUTIC COMPOSITIONS AND METHODS FOR CANCER CHARACTERIZED BY EXPRESSION OF MN / CA IX ANTIGEN ASSOCIATED WITH TUMORS
WO2008103327A2 (en) 2007-02-20 2008-08-28 Bayer Pharmaceuticals Corporation Mn/ca ix and bladder cancer
WO2009056342A1 (en) * 2007-11-02 2009-05-07 Wilex Ag Binding epitopes for g250 antibody

Also Published As

Publication number Publication date
JP5271443B2 (ja) 2013-08-21
US7833728B2 (en) 2010-11-16
US7816493B2 (en) 2010-10-19
EP1487972A2 (en) 2004-12-22
HK1177474A1 (en) 2013-08-23
JP2009114198A (ja) 2009-05-28
AU2003217606B8 (en) 2003-12-12
JP4488351B2 (ja) 2010-06-23
US20050031623A1 (en) 2005-02-10
CA2477163A1 (en) 2003-12-04
EP1487972A4 (en) 2006-05-31
DK3031910T3 (en) 2017-10-23
JP2005535601A (ja) 2005-11-24
HUE026277T2 (en) 2016-05-30
US20080176310A1 (en) 2008-07-24
AU2003217606B2 (en) 2007-11-22
HUE036891T2 (hu) 2018-08-28
JP2013060452A (ja) 2013-04-04
HK1226095B (en) 2017-09-22
US20080176258A1 (en) 2008-07-24
AU2003217606A1 (en) 2003-12-12
DK1487972T3 (en) 2015-10-19
JP2010111679A (ja) 2010-05-20
US7846673B2 (en) 2010-12-07
US20150266971A1 (en) 2015-09-24
JP5199228B2 (ja) 2013-05-15
EP1487972B1 (en) 2015-08-12
AU2003217606A2 (en) 2003-12-12
HUE026218T2 (en) 2016-05-30
JP4514820B2 (ja) 2010-07-28
US20080177046A1 (en) 2008-07-24
WO2004005348A1 (en) 2004-01-15
AU2003217606C1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
US7816493B2 (en) Soluble form of carbonic anhydrase IX (S-CA IX), assays to detect s-CA IX, CA IX'S coexpression with HER-2/NEU/C-ERBB-2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes
HK1226095A1 (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
Gut et al. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9
US20080176268A1 (en) MN Gene and Protein
US7087727B2 (en) Periostin-based diagnostic assays
WO2003100029A2 (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
CA2704273C (en) Mn/ca ix-antibody binding specifically to non-immunodominant epitope of mn/ca ix and uses thereof
AU2008200868B2 (en) Soluble form of carbonic anhydrase IX (s-CA IX), assays to detect s-CA IX, CA IX's coexpression with HER-2/neu/c-erb-B2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes
HK1177474B (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
JP2002515848A (ja) Ｍｎ遺伝子およびｍｎ蛋白質

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210222